Sheila Mikhail, JD, MBA
CEO, President, Founder
Sheila Mikhail co-founded and was initial CEO of AskBio from 2002 through 2007. She left the company to become CEO of NanoCor Therapeutics, Inc., an AskBio spin-out. Most recently, Ms. Mikhail co-founded and was CEO of Bamboo Therapeutics, Inc., which in 20 months raised $50 million, advanced a therapeutic for GAN into the clinic, completed Pre-IND studies for the Duchenne Muscular Dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in August 2016.
Trained as a lawyer, Ms. Mikhail practiced law for over 15 years, including a law firm that she founded, Life Sciences Law, which serviced clients such as Bayer, Gilead, GSK, Sanofi, and Aventis. She also practiced with Ropes and Gray in Boston. Ms. Mikhail earned a JD, with honors, from Northwestern University; a finance MBA, with honors, from the University of Chicago; and a BS, with highest honors, from the University of Illinois at Urbana-Champaign.
Philippe Moullier, MD, PhD
Chief Scientific Officer
Founder and until Dec. 2016, the Director of the research INSERM Unit UMR 1089 entitled « Translational Gene Therapy for Retinal and Neuromuscular Diseases » at the University of Nantes, France. He was also the Scientific Director of GENETHON, a nonprofit research institution, located near Paris, from Jan 2009 through Dec 2011. In 2014, he co-founded HORAMA, a spin-off dedicated to gene therapy for monogenic rare retinal diseases. He established a unique 16,150 ft2 BL2/BL3 confined large animal core facility located at the Nantes veterinary school. He was also key in the establishment of a full GMP-compliant manufacturing facility operated today by the Etablissement Français du Sang (EFS) located in Nantes. From 2006 until Jan 2016, Dr. Moullier was an Adjunct Professor at the Molecular Genetics and Microbiology Department at the University of Florida, USA. Dr. Moullier supervised more than 85 people scattered among the research groups in Nantes, the core facilities and administration, including junior faculty, post-docs, graduate students, undergraduate students, and technicians. His research efforts are focused on: (i) the basic virology of Adeno-Associated Virus with translational developments in recombinant virus assembly; (ii) the preclinical evaluation of recombinant viral vectors in large animal models of rare genetic disorders; (iii) the establishment of Phase I/II human clinical trials in retina and neuromuscular diseases; and (iv) basic viral vector biology (immunology and vector maintenance) in large animal models. Prior to joining the University of Nantes, Dr. Moullier conducted research at the Pasteur Institute in Paris and at the Wistar Institute in Philadelphia where he was engaged in the development of MLV and adenovirus-derived recombinant viral vectors and their in vivo application.
Dr. Moullier was a postdoctoral fellow at Scripps Research Institute in La Jolla, received his PhD degree in Biochemistry from the University of Paris (Mentor Pr Donny Strosberg) and obtained a Master in Immunology at the Pasteur Institute. He also was an intern in nephrology and internal medicine, and received his MD degree from the University of Paris (mentor: Pr Claude Amiel). Dr. Moullier has authored over 120 original publications describing virus biology, viral vector development, gene transfer and genetic diseases. He served as an expert to the EMA and at the ANSM Gene Therapy Advisory Board and is a world-renowned expert in viral vector development and in gene therapy translational research.
Rhonda L. Stanley
Chief Financial Officer
Ms. Rhonda L. Stanley has over 25 years of financial leadership experience in public and private companies. She previously served as the CFO of Bamboo Therapeutics, Inc. a privately held gene therapy company which was sold to Pfizer, Inc. in 2016. In addition, she has served as Corporate Controller and Treasurer of several publicly traded and venture-backed biotechnology companies including Nephrogenex, Inc (NASDAQ: NRX), Tranzyme, Inc. (NASDAQ: TZYM), Pozen Inc. (NASDAQ: POZN) and Aldagen, Inc.
Ms. Stanley has led several companies through an initial public offering including establishing public company reporting requirements and Sarbanes-Oxley compliance. She served as the Principal Financial and Accounting Officer of Tranzyme Inc. where she played an integral role in leading Tranzyme Inc., an international pharmaceutical company, through a reverse merger with Ocera Therapeutics in 2013 (NASDAQ: OCRX). Ms. Stanley has an accounting degree from Bradley University, holds an MBA, is a certified public accountant and a registered nurse. In addition, she served as a Captain in the U.S. Army finance corp.
Josh Grieger, PhD
Chief Technology Officer
Josh Grieger was the co-founder and Vice President of Process Development and Manufacturing with Bamboo Therapeutics, Inc. Within this structure, Josh led and managed the GMP manufacturing and quality release of the rAAV drug product for the GAN Phase I clinical trial and supported the Pre-IND for Duchenne Muscular Dystrophy AAV gene therapy program. Bamboo Therapeutics, Inc was acquired by Pfizer in August 2016. As part of Pfizer, Josh served as a Senior Director of Gene Therapy focused on process development and optimization of scalable rAAV vector manufacturing processes for early and late phase gene therapy clinical trials.
From 2008 through 2015, Josh was employed by the UNC-Chapel Hill Gene Therapy Center functioning as a post-doctoral research scientist, Research Associate Professor and Research Assistant Professor (Director of UNC Vector Core facility). His research focused on the development of scalable transfection-based manufacturing process for rAAV vectors. The Pro10 cell line was established through this work and led to the transition from adherent cell based manufacturing of rAAV vectors to animal derived component free suspension cell manufacturing in WAVE and Stir tank bioreactors with associated scalable purification technology. Josh also consulted for Asklepios Biopharmaceuticals over this time and was key in the Pro10 rAAV vector manufacturing process technology transfer to Baxter to support the Hemophilia gene therapy pre-clinical and clinical programs.
Josh received his Doctorate Degree from UNC-Chapel Hill in the Molecular Biology and Genetics Program in 2005. He carried out his Doctoral dissertation work in Dr. R. Jude Samulski’s laboratory focused on various aspects of the AAV life-cycle.